Previous 10 | Next 10 |
– LINZESS (Iinaclotide) EUTRx prescription demand growth increased 9% year-over-year; LINZESS U.S. net sales of $270 million, an increase of 9% year-over-year – – Expands clinical utility of LINZESS with FDA approval for pediatric patients ages 6-17 years-old sufferin...
2023-08-07 14:36:26 ET Ironwood Pharmaceuticals ( NASDAQ: IRWD ) is scheduled to announce Q2 earnings results on Tuesday, August 8th, before market open. The consensus EPS Estimate is $0.25 (+19.0% Y/Y) and the consensus Revenue Estimate is $103.72M (+6.7% Y/Y). Over t...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2023 investor update conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, August 8, 2023. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and Canada) o...
2023-07-19 11:00:00 ET Summary Pharmaceuticals/biotechnology is the most attractive subsector regarding both value and quality scores. Healthcare equipment is the most overpriced healthcare industry. Fast facts on iShares U.S. Healthcare ETF. 10 healthcare stocks cheaper t...
Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastroint...
2023-06-19 05:16:46 ET Summary Pharma/biotechnology and healthcare providers are slightly undervalued relative to 11-year averages. Healthcare equipment is the most overvalued subsector. Fast facts on PBE, a genomics ETF. 10 healthcare stocks cheaper than their peers in Ju...
Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastroint...
2023-06-12 17:53:16 ET The US Food and Drug Administration has expanded its approval of Ironwood Pharmaceuticals' ( NASDAQ: IRWD ) drug Linzess to include the treatment of functional constipation in children and teens. Linzess was already approved to treat adults with irritable ...
– LINZESS is the first and only FDA-approved prescription therapy for functional constipation in this patient population – – Approval brings a much-needed option to an estimated 6 million 6-17-year-olds in the U.S. 1 affected by this chronic, prevalent condition &...
2023-06-12 09:54:54 ET Despite having a successful drug on the market and making a major acquisition recently, share prices of Ironwood Pharmaceuticals (NASDAQ: IRWD) are down by 7% this year so far. Wall Street analysts take a gloomy view of its future, with average estimates calli...
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-22 07:00:07 ET Mohit Bansal from Wells Fargo issued a price target of $14.00 for IRWD on 2024-05-22 05:13:00. The adjusted price target was set to $14.00. At the time of the announcement, IRWD was trading at $6.78. The overall price target consensus is at $16.00 ...